UNSPSC 51401550: Triazolam

This classification denotes a benzodiazepine with the molecular formula C17H12Cl2N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HM943223R, chemically known as 8-chloro-6-(o-chlorophenyl)-1-methyl-4h-s-triazolo(4,3-a)(1,4)benzodiazepine but generally known as triazolam, which bears US NIH Compound Identifier 5556. European Medicines Agency schedules Triazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11258MIG.

UNSPSC 51401550 Triazolam is a Commodity code representing pharmaceutical products state and local governments procure for public health, community health, and emergency response programs. Recent opportunities show state and local buyers acquiring naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through competitive bidding and cooperative purchasing vehicles. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). Vendors must comply with FDA requirements, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, E-Verify, drug-free workplace certification, and maintain substantial insurance coverage including commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000. Contracts typically include probationary periods, performance penalties for compliance failures, and fixed-fee or net-pricing models with administrative fees.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually via IFB60459723LAS, an IFB with response due July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building and potential FEMA funding. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling exploratory procurement strategy before formal RFP issuance. The Minnesota Department of Administration's MMCAP posted RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and a two-year initial term. Vendors must supply through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with pricing weighted 75 percent in evaluation.